{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.29","upperLimit":"9.66","value":"7.33"},{"groupId":"OG001","lowerLimit":"1.87","upperLimit":"14.29","value":"6.44"},{"groupId":"OG002","lowerLimit":"1.84","upperLimit":"5.52","value":"3.88"},{"groupId":"OG003","lowerLimit":"3.45","upperLimit":"5.39","value":"3.68"},{"groupId":"OG004","lowerLimit":"1.64","upperLimit":"9.00","value":"3.02"},{"comment":"N/A=NE=not estimable due to insufficient number of participants with events","groupId":"OG005","lowerLimit":"2.89","upperLimit":"NA","value":"4.63"},{"comment":"N/A=NE=not estimable due to insufficient number of participants with events","groupId":"OG006","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"groupId":"OG007","lowerLimit":"1.77","upperLimit":"5.49","value":"2.83"},{"groupId":"OG008","lowerLimit":"1.81","upperLimit":"14.85","value":"5.62"},{"groupId":"OG009","lowerLimit":"3.02","upperLimit":"9.10","value":"5.36"},{"groupId":"OG010","lowerLimit":"1.68","upperLimit":"5.75","value":"3.65"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"62"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"27"},{"groupId":"OG004","value":"9"},{"groupId":"OG005","value":"9"},{"groupId":"OG006","value":"26"},{"groupId":"OG007","value":"12"},{"groupId":"OG008","value":"12"},{"groupId":"OG009","value":"9"},{"groupId":"OG010","value":"28"}],"units":"Participants"}],"description":"TTP was defined as time from the first day of study treatment to the first occurrence of progressive disease (PD). RECIST v1.1: PD: at least a 20% increase in the sum of diameters of target lesions and an absolute increase of at least 5 mm. IMWG: PD: increase of \\>/= 25% from lowest response value in serum or urine M-protein or bone marrow plasma cell percentage or development of new or increase in size of bone lesions or soft tissue plasmacytomas.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with NSCLC were treated with vemurafenib monotherapy.","id":"OG000","title":"Cohort 1: Non-Small Cell Lung Cancer (NSCLC) - Vemurafenib"},{"description":"Participants with ovarian cancer were treated with vemurafenib monotherapy.","id":"OG001","title":"Cohort 2: Ovarian Cancer - Vemurafenib"},{"description":"Participants with colorectal cancer were treated with vemurafenib monotherapy.","id":"OG002","title":"Cohort 3a: Colorectal Cancer - Vemurafenib"},{"description":"Participants with colorectal cancer were treated with vemurafenib and cetuximab combination therapy.","id":"OG003","title":"Cohort 3b: Colorectal Cancer - Vemurafenib + Cetuximab"},{"description":"Participants with cholangiocarcinoma were treated with vemurafenib monotherapy.","id":"OG004","title":"Cohort 4: Cholangiocarcinoma - Vemurafenib"},{"description":"Participants with multiple myeloma were treated with vemurafenib monotherapy.","id":"OG005","title":"Cohort 6: Multiple Myeloma - Vemurafenib"},{"description":"Participants with Erdheim-Chester disease (ECD) or Langerhans cell histiocytosis (LCH) were treated with vemurafenib monotherapy.","id":"OG006","title":"Cohort 7a: ECD/LCH - Vemurafenib"},{"description":"Participants with anaplastic thyroid cancer were treated with vemurafenib monotherapy.","id":"OG007","title":"Cohort 7b: Anaplastic Thyroid Cancer - Vemurafenib"},{"description":"Participants with advanced stage astrocytoma were treated with vemurafenib monotherapy.","id":"OG008","title":"Cohort 7c: Advanced Stage Astrocytoma - Vemurafenib"},{"description":"Participants with early stage astrocytoma were treated with vemurafenib monotherapy.","id":"OG009","title":"Cohort 7d: Early Stage Astrocytoma - Vemurafenib"},{"description":"Participants with other BRAF V600-positive tumors were treated with vemurafenib monotherapy.","id":"OG010","title":"Cohort 7: Other BRAF V600-positive Tumors - Vemurafenib"}],"paramType":"MEDIAN","populationDescription":"ITT population included all participants enrolled in the study irrespective of whether they had received study medication or not.","reportingStatus":"POSTED","timeFrame":"Up to approximately 3 years","title":"Time to Tumor Progression (TTP)","type":"SECONDARY","unitOfMeasure":"months"}